Christopher J. Ott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher J. Ott has a total of 406 co-authors. Here are the top co-authors by number of shared publications:
- Aaron N. Hata
Massachusetts General Hospital 7 Charlestown, MA
13 shared publications - Cyril H. Benes
Massachusetts General Hospital, Harvard Medical School, Boston, USA
12 shared publications - Anjali Shinde
Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Radiation Oncology, Mass General Hospital, Boston, MA, USA
11 shared publications - Eva Volckova
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
11 shared publications - Henning Willers
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
11 shared publications - Jianli Ma
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
11 shared publications
Latest Publications
- 7 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF26
Systematic Targeting of Protein Complexes with Molecular COUPLrs
Small molecules that modulate protein complexes have transformed cell biology and oncology, yet few chemical starting points exist to probe protein–protein interactions. To expand this space, we developed molecular COvalent Protein Ligators (COUPLr), elaborated small molecules flanked by two cysteine-reactive warheads. Using COuplr NEtwork deteCTor (CONNECT), an integrated chemical proteomic platform that identifies proteins and complexes amenable to coupling, we revealed 171 targetable protein classes, including mutant-selective complexes and assemblies not traditionally addressed by small molecules. We then optimized a COUPLr against the oncogenic fusion EML4–ALK. This compound engages EML4–ALK by binding its EML4 domain, remodeling protein dynamics, disrupting downstream signaling, and inducing proteasome-mediated degradation of the fusion. Finally, we show that FDA-approved drugs can be converted into COUPLrs to degrade their targets, indicating that this modality can endow existing therapeutics with new functional properties. Overall, molecular COUPLrs offer an unbiased framework to discover, characterize, and pharmacologically exploit protein complexes. Significance: Developing drugs against multi-protein complexes is traditionally challenging. In this study, we develop molecular COUPLrs, dual cysteine-reactive small molecules, that can engage complexes across the proteome. As proof of concept, we designed COUPLrs targeting EML4–ALK and show that COUPLrs can reshape protein dynamics, drive degradation, and reprogram approved drugs.
- 7 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF26
Systematic Targeting of Protein Complexes with Molecular COUPLrs
Small molecules that modulate protein complexes have transformed cell biology and oncology, yet few chemical starting points exist to probe protein–protein interactions. To expand this space, we developed molecular COvalent Protein Ligators (COUPLr), elaborated small molecules flanked by two cysteine-reactive warheads. Using COuplr NEtwork deteCTor (CONNECT), an integrated chemical proteomic platform that identifies proteins and complexes amenable to coupling, we revealed 171 targetable protein classes, including mutant-selective complexes and assemblies not traditionally addressed by small molecules. We then optimized a COUPLr against the oncogenic fusion EML4–ALK. This compound engages EML4–ALK by binding its EML4 domain, remodeling protein dynamics, disrupting downstream signaling, and inducing proteasome-mediated degradation of the fusion. Finally, we show that FDA-approved drugs can be converted into COUPLrs to degrade their targets, indicating that this modality can endow existing therapeutics with new functional properties. Overall, molecular COUPLrs offer an unbiased framework to discover, characterize, and pharmacologically exploit protein complexes. Significance: Developing drugs against multi-protein complexes is traditionally challenging. In this study, we develop molecular COUPLrs, dual cysteine-reactive small molecules, that can engage complexes across the proteome. As proof of concept, we designed COUPLrs targeting EML4–ALK and show that COUPLrs can reshape protein dynamics, drive degradation, and reprogram approved drugs.
- Open Access
- 1 August 2026
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 12 (8) , 1195-1206
A Dimeric Protein-RNA Glue Promotes Multivalent eIF4A-RNA Assembly
Ligand dimerization represents a powerful strategy to enhance avidity, potency, and selectivity. Leveraging the natural-product molecular glue rocaglamide (RocA), we identified BisRoc, a dimeric rocaglate ligand that potently and durably suppresses translation and exhibits greater specificity across a cancer cell line panel than the monomeric RocA. CRISPRi screening revealed that BisRoc activity is influenced by cellular context, including IFITM-mediated uptake, ABC-type efflux transporters, and the translation initiation factor eIF4A2. Mechanistic studies showed that the paralogs eIF4A1 and eIF4A2 are differentially sensitive to BisRoc-induced dimerization. Owing to the presence of multiple binding sites on RNAs, BisRoc-bridged eIF4A-RNA motifs assemble into higher-order complexes that promote stress-granule formation more efficiently than monomeric RocA. Given the widespread multivalency of RNA-RBP interactions, this ligand dimerization strategy may be extended to modulate the higher-order assembly of other RNA-binding proteins.
- 1 August 2026
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 12 (8) , 1195-1206
Open AccessA Dimeric Protein-RNA Glue Promotes Multivalent eIF4A-RNA Assembly
Ligand dimerization represents a powerful strategy to enhance avidity, potency, and selectivity. Leveraging the natural-product molecular glue rocaglamide (RocA), we identified BisRoc, a dimeric rocaglate ligand that potently and durably suppresses translation and exhibits greater specificity across a cancer cell line panel than the monomeric RocA. CRISPRi screening revealed that BisRoc activity is influenced by cellular context, including IFITM-mediated uptake, ABC-type efflux transporters, and the translation initiation factor eIF4A2. Mechanistic studies showed that the paralogs eIF4A1 and eIF4A2 are differentially sensitive to BisRoc-induced dimerization. Owing to the presence of multiple binding sites on RNAs, BisRoc-bridged eIF4A-RNA motifs assemble into higher-order complexes that promote stress-granule formation more efficiently than monomeric RocA. Given the widespread multivalency of RNA-RBP interactions, this ligand dimerization strategy may be extended to modulate the higher-order assembly of other RNA-binding proteins.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Contents of Supplementary Tables from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
List of contents of each Supplementary Table
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessContents of Supplementary Tables from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
List of contents of each Supplementary Table
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S7 from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
Supplementary Table S1. List of SsTOP genes Supplementary Table S2. List of SsTOP (-E2F) genes Supplementary Table S3A. TF activity DMSO vs PKAi Supplementary Table S3B. TF activity PKAi+SIKi (COMBO) vs PKAi Supplementary Table S3A. CRTC2 targets gene set Supplementary Table S4. Curated FLC gene sets Supplementary Table S5. Expression of amino acid metabolism/urea cycle genes in FLC Supplementary Table S6. Regulation of curated FLC pathways by PKAi and SIKi in FLX1 Supplementary Table S7. MSigDB (Human) Hallark_E2F targets gene set
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S7 from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
Supplementary Table S1. List of SsTOP genes Supplementary Table S2. List of SsTOP (-E2F) genes Supplementary Table S3A. TF activity DMSO vs PKAi Supplementary Table S3B. TF activity PKAi+SIKi (COMBO) vs PKAi Supplementary Table S3A. CRTC2 targets gene set Supplementary Table S4. Curated FLC gene sets Supplementary Table S5. Expression of amino acid metabolism/urea cycle genes in FLC Supplementary Table S6. Regulation of curated FLC pathways by PKAi and SIKi in FLX1 Supplementary Table S7. MSigDB (Human) Hallark_E2F targets gene set
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S8 from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
Supplementary Figure S1: Validation of the specificity of the p-SIK Ser343 antibody. Supplementary Figure S2. PKAfus inactivates SIKs to support tumor cell growth in vitro and in vivo. Supplementary Figure S3. PKAfus reprograms transcription by inactivating SIK and stimulating CRTC2. Supplementary Figure S4. CRTC2/CREB mediates transcriptional regulation downstream of PKAfu. Supplementary Figure S5. CRTC2/CREB supports tumor cell growth downstream of PKAfus. Supplementary Figure S6. Primary FLC tumors show deregulation of SIK/CRTC2- controlled genes. Supplementary Figure S7. PKAfus driven tumors are sensitive to p300 inhibition. Supplementary Figure S8. PKAfus driven tumors are sensitive to p300 inhibition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S8 from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
Supplementary Figure S1: Validation of the specificity of the p-SIK Ser343 antibody. Supplementary Figure S2. PKAfus inactivates SIKs to support tumor cell growth in vitro and in vivo. Supplementary Figure S3. PKAfus reprograms transcription by inactivating SIK and stimulating CRTC2. Supplementary Figure S4. CRTC2/CREB mediates transcriptional regulation downstream of PKAfu. Supplementary Figure S5. CRTC2/CREB supports tumor cell growth downstream of PKAfus. Supplementary Figure S6. Primary FLC tumors show deregulation of SIK/CRTC2- controlled genes. Supplementary Figure S7. PKAfus driven tumors are sensitive to p300 inhibition. Supplementary Figure S8. PKAfus driven tumors are sensitive to p300 inhibition.
- Open Access
- 2 June 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (6) , 117464
An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma
- 2 June 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (6) , 117464
Open AccessAn orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Differentially expressed proteins in ID2 OE cells (24 hours after induction with doxycycline).
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Differentially expressed proteins in ID2 OE cells (24 hours after induction with doxycycline).
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
MAGeCK analysis for CRISPRa screen.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
MAGeCK analysis for CRISPRa screen.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Transcription factor footprinting and chromatin accessibility in MM cells overexpressing ID2, obtained through ATAC-seq analysis.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Transcription factor footprinting and chromatin accessibility in MM cells overexpressing ID2, obtained through ATAC-seq analysis.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S6 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Supplementary Figure S1. Discovery of ID2 as a putative tumor suppressor in MM. Supplementary Figure S2. ID2 expression causes cell cycle arrest in MM cells. Supplementary Figure S3. Induced ID2 expression in MM cells is associated with senescence-like features. Supplementary Figure S4. TCF3 is a highly expressed selective dependency in MM cells. Supplementary Figure S5. Depletion of TCF3 phenocopies effects of ID2 overexpression in MM cells. Supplementary Figure S6. The bone marrow milieu has a role in supporting TCF3 activity in MM.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S6 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Supplementary Figure S1. Discovery of ID2 as a putative tumor suppressor in MM. Supplementary Figure S2. ID2 expression causes cell cycle arrest in MM cells. Supplementary Figure S3. Induced ID2 expression in MM cells is associated with senescence-like features. Supplementary Figure S4. TCF3 is a highly expressed selective dependency in MM cells. Supplementary Figure S5. Depletion of TCF3 phenocopies effects of ID2 overexpression in MM cells. Supplementary Figure S6. The bone marrow milieu has a role in supporting TCF3 activity in MM.